Table 4 High quality studies diagnostic accuracy measures (non-Siemens Enzygnost/Dade Behring only)

Goncalves 1999 [48]

43

11-14 m

Diagnostica Merck

 < 40 mIU/mL

 ≥ 40 mIU/mL

NR

0

1

4

38

0.0(0.0–60.2)^c

97.4 (86.5–99.9)

0.0 (0.0–97.5)^c

90 .5(77.4–97.3)^c

NR

NR

 < 100 mIU/mL

 ≥ 100 mIU/mL

NR

0

0

1

42

0.0(0.0–97.5)^c

100.0 (91.6–100.0)^c

NE

97.7 (87.7–99.9)^c

NR

NR

Ratnam 1995 [63]

229

1-16yrs

Diamedix

 < 15 EIA unit

 ≥ 120 mIU/mL

Excluded

165

21

3

30

98.2 (94.9–99.6)

58.8 (44.2–72.4)

88.7 (83.3–92.9)

90.9 (75.7–98.1)

NR

NR

 ≥ 8 mIU/mL

Excluded

185

1

18

15

91.1 (86.3–94.7)

93.8 (69.8–100.0)

99.5 (97.0–100.0)

45.5 (28.1–63.6)

NR

NR

Dorigo-Zetsma 2015 [45]

154

 ≥ 18yrs

Diasorin

 < 13.5 AU/ml

 ≥ 120 mIU/mL

Grouped with positives

136

0

17

1

88.9 (82.8–93.4)

100.0 (2.5–100.0)^c

100.0 (97.3–100.0)^c

5.6 (0.1–27.3)^c

NR

NR

Mao 2009 [56]

52

NR

German Virion/Serion

 < 150 mIU/mL

 ≥ 1: 4^b

NR

37

0

2

13

94.9 (82.7–99.4)

100.0 (75.3–100.0)

100.0 (90.5–100.0)

86.7 (59.5–98.3)

0.90

0.88

47

NR

IBL kit

 < 8 U (unit) / ml

 ≥ 1: 4^b

NR

20

0

14

13

58.8 (40.7–75.4)

100.0 (75.3–100.0)

100.0 (83.2–100.0)

48.1 (28.7–68.1)

0.44

0.85

Ratnam 1995 [63]

229

1-16yrs

Measlestat

 ≤ 0.79 Predicted value index

 ≥ 120 mIU/mL

Excluded

132

2

22

53

85.7 (79.2–90.8)

96.4 (87.5–99.6)

98.5 (94.7–99.8)

70.7 (59.0–80.6)

NR

NR

 ≥ 8 mIU/mL

Excluded

134

0

58

17

69.8 (62.8–76.2)

100.0 (80.5–100.0)

100.0 (97.3–100.0)

22.7 (13.8–33.8)

NR

NR

Cohen 2006 [25]

100

NR

Microimmun

 < 1.1 O.D

Batch specific cut off^a

Grouped with positives

69

0

8

23

89.6 (80.6–95.4)

100.0 (85.2–100.0)

100.0 (94.8–100.0)^c

74.2 (55.4–88.1)^c

NR

72.0%

Fowlkes 2011 [47]^e

2344

6- 36 m; mothers (age NR)

Trinity

NR

 ≥ 120 mIU/mL

NR

1412

70

135

727

91.3 (89.8–92.6)

91.2 (89.0–93.1)

95.3 (94.1–96.3)^c

84.3 (81.7–86.7)^c

NR

NR

Ratnam 1995 [63]

229

1-16yrs

Vidas

 < 0.5 Test value threshold

 ≥ 120 mIU/mL

Excluded

144

3

15

52

90.6 (84.9–94.6)

94.5 (84.9–98.9)

98.0 (94.2–99.6)

77.6 (65.8–86.9)

NR

NR

 ≥ 8 mIU/mL

Excluded

147

0

50

17

74.6 (67.9–80.5)

100.0 (80.5–100.0)

100.0 (97.5–100.0)

25.4 (15.5–37.5)

NR

NR

Dorigo-Zetsma 2015 [45]

154

 ≥ 18yrs

Vidas

 < 0.5 Test values (TV)

 ≥ 120 mIU/mL

Grouped with positives

137

0

16

1

89.5 (83.6–93.9)

100.0 (2.5–100.0)^c

100.0 (97.3–100.0)^c

5.9 (0.1–28.7)^c

NR

NR

Hatchette 2017 [26]

148

NR

BioPlex 2200

 < 0.13 AU/mL

 > 192 mIU/mL^b

Grouped with negatives

55

0

30

63

64.7 (53.6–74.8)

100.0 (94.3–100.0)

100.0 (93.5–100.0)^c

67.7 (57.3–77.1)^c

NR

0.64

Dorigo-Zetsma 2015 [45]

154

 ≥ 18yrs

In house MBA (MIA)

 < 120 mIU/mL

 ≥ 120 mIU/mL

Grouped with positives

149

0

4

1

97.4 (93.4–99.3)^c

100.0 (2.5–100.0)^c

100.0 (97.6–100.0)^c

20.0 (0.5–71.6)^c

NR

NR

Coughlin 2021 [19]

140

6 m—adults

In house MBA

(MeV N)

 < 9.5 mIU/mL

 ≥ 120 mIU/mL^b

NR

84

9

12

35

87.5 (79.2–93.4)

79.5 (64.7–90.2)

90.3 (82.4–95.5)

74.5 (59.7–86.1)

NR

0.431

In house MBA

(MeV WVA_L)

 < 137 mIU/mL

 ≥ 120 mIU/mL^b

NR

91

11

5

33

94.8 (88.3–98.3)

75.0 (59.7–86.8)

89.2 (81.5–94.5)

86.8 (71.9–95.6)

NR

0.827

Coughlin 2021 [19]

212

6 m—adults

In house MBA (MeV WVA_L)

 < 137 mIU/mL

 ≥ 120 mIU/mL^b

NR

119

12

6

75

95.2 (89.8–98.2)

86.2 (77.1–92.7)

90.8 (84.5–95.2)

92.6 (84.6–97.2)

NR

0.768

In house MBA (MeV WVA_C)

 < 153 mIU/mL

 ≥ 120 mIU/mL^b

NR

119

16

6

71

95.2 (89.8–98.2)

81.6 (71.9–89.1)

88.1 (81.5–93.1)

92.2 (83.8–97.1)

NR

0.716

deSouza 1991 [44]

181

 < 18 yrs

In house EIA

DOD reading: ≤ 0.12

NR

NR

177

0

2

2

98.9 (96.0–99.9)

100.0 (15.8–100.0)^c

100.0 (97.9–100.0)^c

50 .0 (6.8–93.2)^c

NR

0.81

Lee 1999 [54]^f

85

NR

In house EIA

 < 200 mIU/mL

 > 200 mIU/mL^b

NR

68

0

1

16

98.6 (92.2–100.0)

100.0 (79.4–100.0)

100.0 (94.7–100.0)

94.1 (71.3–99.9)

0.98

NR